Cambrex — Merger or Acquisition (October 2006)
16 slides from Cambrex's merger presentation, Oct 24, 2006
Slide 1: Update on Strategic Alternatives Process
Update on Strategic Alternatives Process October 24, 2006
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, including, without limitation, statements regarding expected performance, especially
Slide 3: Good for Cambrex Stockholders
Good for Cambrex Stockholders Full and fair value for two businesses sold after thorough process Substantial special cash dividend to stockholders of $13.50 to $14.50 per share expected Continuing equity interest in more focused and streamlined Human Health business
Slide 4: Process Overview: Exploration of Strategic Alternatives
Process Overview: Exploration of Strategic Alternatives Cambrex undertook a thorough exploration of strategic alternatives beginning with a public announcement in January 2006 Cambrex announced in February 2006 that Bear Stearns was retained to advise on options for maximizing stockholder value Indi
Slide 5: Conclusions of Strategic Review
Conclusions of Strategic Review No firm bid for entire Company at fair value Sale of Bio Businesses to Lonza represents most effective means of maximizing stockholder value Sale of Cork and Landen facilities will improve Human Health profitability and cash flow Continued operation of Human Health ex
Slide 6: Bio Businesses: Key Transaction Terms
Bio Businesses: Key Transaction Terms Sale of Bio Businesses to Lonza for cash consideration of $460 million Tax-efficient transaction with net proceeds of approximately $450 million All liabilities of Bio Businesses assumed by buyer other than taxes and certain employee benefits obligations incurre
Slide 7: Creating Stockholder Value: Sale of Bio Businesses
Creating Stockholder Value: Sale of Bio Businesses Premium valuation: 15 X LTM EBITDA Unlocks value of Bioproducts business Eliminates cash and profitability drain of Biopharma business Removes execution risk in selling Biopharma business separately Negligible tax leakage Excellent "public company"
Slide 8: Creating Stockholder Value: Sale of Cork and Landen
Creating Stockholder Value: Sale of Cork and Landen Challenged by mature product lines High capex requirements Avoided plant shutdown costs of $20 to $25 million Eliminated businesses with: 2005 operating loss of $5.0 million* 2005 negative cash flow of $2.3 million* *Note: Pro forma values exclude
Slide 9: Creating Stockholder Value: Recapitalization / Dividend Distribution
Creating Stockholder Value: Recapitalization / Dividend Distribution Shortly after closing, Cambrex plans to borrow $125 - $150 million (subject to availability on favorable terms) Net proceeds from sale and expected debt financing will fund special dividend Distribute approximately $13.50 to $14.50
Slide 10: Creating Stockholder Value: Focus on Human Health Business
Creating Stockholder Value: Focus on Human Health Business Profitable, focused business in growing markets Focus on niche growth markets (High Potency, High Containment, Tastemasking and DEA Controlled Substances) Premier generic API business Industry-leading sales growth and EBITDA margins Four fac
Slide 11: Cambrex Path Forward
Cambrex Path Forward Build world-class pharma services business Capitalize on expected growth in API market Leverage strong custom development pipeline Rebalance product line Place immediate emphasis on: Annual corporate cost reduction of $8 million Operational improvements Pursue accretive, bolt-on
Slide 12: Pro Forma Post-Divestiture Financials
Pro Forma Post-Divestiture Financials In US$ (millions) FY 2005 June YTD 2006 Sales 223.8 117.2 Gross Profit 86.3 41.9 EBIT 33.0 16.3 EBITDA 53.3 25.9 Capex 19.3 9.3 NOTE: The data presented above assumes the BioPharma, Bioproducts, Cork, Ireland and Landen, Belgium businesses were divested as of 1/
Slide 13: Roadmap to Completion
Roadmap to Completion File preliminary proxy materials with SEC Obtain other regulatory clearances Clear proxy materials with SEC / mail to stockholders Conduct stockholder vote at special meeting Close transaction (expected in 90 to 120 days) Arrange debt financing Distribute dividend to stockholde
Slide 14: Corporate Governance Initiatives
Corporate Governance Initiatives Ongoing commitment to be responsive to stockholders and implement best practices in corporate governance Proposal to declassify Board at 2007 Annual Meeting of Stockholders If approved, Board also expects to implement majority voting for Directors
Slide 15: Good for Cambrex Stockholders
Good for Cambrex Stockholders Full and fair value for two businesses sold after thorough process Substantial special cash dividend to stockholders of $13.50 to $14.50 per share expected Continuing equity interest in more focused and streamlined Human Health business
Slide 16: Proxy Statement and Participants in Solicitation
Proxy Statement and Participants in Solicitation Proxy Statement Cambrex Corporation plans to file with the SEC and mail to its stockholders a Proxy Statement in connection with a special meeting of stockholders to be called to approve the Bio Businesses transaction. The Proxy Statement will contain